Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 3 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

Recs

0
Player Avatar Kebin008 (< 20) Submitted: 12/17/2012 11:35:53 PM : Outperform Start Price: $8.74 AMRN Score: -117.29

Vacepa is an extremely valuable asset Amarin has. I remain bullish on this stock given the CEO Joe Z's background with acquisitions. It is difficult to value the company given the uncertainty surrounding NCE status. Given the extended delay from the FDA, I believe that NCE will be granted in the end. The FDA may just simply be looking for a way to grant Amarin this designation. Furthermore, I believe that the acquisition talks will progress in a much more progressive manner once NCE status has been decided. At the current price, Amarin has great upside potential with limited downside risks.

Featured Broker Partners


Advertisement